Evaluation of colloidal silica suspension as efficient additive for improving physicochemical and in vitro biological properties of calcium sulfate-based nanocomposite bone cement.
In the present study new calcium sulfate-based nanocomposite bone cement with improved physicochemical and biological properties was developed. The powder component of the cement consists of 60 wt% α-calcium sulfate hemihydrate and 40 wt% biomimetically synthesized apatite, while the liquid component consists of an aqueous colloidal silica suspension (20 wt%). In this study, the above mentioned powder phase was mixed with distilled water to prepare a calcium sulfate/nanoapatite composite without any additive. Structural properties, setting time, compressive strength, in vitro bioactivity and cellular properties of the cements were investigated by appropriate techniques. From X-ray diffractometer analysis, except gypsum and apatite, no further phases were found in both silica-containing and silica-free cements. The results showed that both setting time and compressive strength of the calcium sulfate/nanoapatite cement improved by using colloidal silica suspension as cement liquid. Meanwhile, the condensed phase produced from the polymerization process of colloidal silica filled the micropores of the microstructure and covered rodlike gypsum crystals and thus controlled cement disintegration in simulated body fluid. Additionally, formation of apatite layer was favored on the surfaces of the new cement while no apatite precipitation was observed for the cement prepared by distilled water. In this study, it was also revealed that the number of viable osteosarcoma cells cultured with extracts of both cements were comparable, while silica-containing cement increased alkaline phosphatase activity of the cells. These results suggest that the developed cement may be a suitable bone filling material after well passing of the corresponding in vivo tests.
Borhan
Shokoufeh
S
Ceramics Department, Materials and Energy Research Center, P.O. Box 14155-4777, Tehran, Iran.
Hesaraki
Saeed
S
Ahmadzadeh-Asl
Shaghayegh
S
D001843:Bone Cements / Q000032:analysis* / Q000737:chemistry* / Q000494:pharmacology; D002133:Calcium Sulfate / Q000737:chemistry*; D002478:Cells, Cultured; D055598:Chemical Phenomena; D020099:Coated Materials, Biocompatible / Q000032:analysis / Q000737:chemistry / Q000494:pharmacology; D003102:Colloids / Q000032:analysis / Q000737:chemistry; D019245:Compressive Strength / Q000502:physiology; D004526:Efficiency; D006801:Humans; D008422:Materials Testing; D053761:Nanocomposites / Q000737:chemistry; D010006:Osteoblasts / Q000187:drug effects / Q000502:physiology; D012822:Silicon Dioxide / Q000032:analysis* / Q000737:chemistry; D013499:Surface Properties; D013535:Suspensions
D001843:Bone Cements; D020099:Coated Materials, Biocompatible; D003102:Colloids; D013535:Suspensions; D012822:Silicon Dioxide; D002133:Calcium Sulfate